Lilly Oncology Support Center
Eli Lilly and Company, through Lilly Oncology, offers financial assistance to qualified patients who are prescribed oncology medications and who need help paying for their medications. The complete list of Lilly Oncology drugs and their patient support programs is provided in the Table.
Lilly Oncology Support Center
The Lilly Oncology Support Center provides services to patients and providers, including assistance with infused products, the Retevmo Support Program, the Verzenio Continuous Care support program, and the Lilly Cares Foundation.
Infused Products Enrollment Form
By enrolling in the Lilly Oncology Support Center, patients may receive various forms of support and information to help access infused oncology products, including benefits investigation support, financial support, and ongoing support. To enroll your patient, complete the application and fax to 877-366-0585.
Retevmo Support Program
This program provides ongoing support services for patients who have been prescribed Retevmo, including benefits investigation support, the MyRightDose Program, the Retevmo Interim Access Program support, and other support services. To enroll your patient, complete the application and fax to 877-427-4030.
The Retevmo MyRightDose Program allows patients who are prescribed Retevmo to continue therapy with Retevmo at the appropriate dose, without delays or costs to the patient. Retevmo can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program. To be eligible for the program, patients must:
- Return unused pills in the preaddressed envelope, according to the instructions provided
- Be aged ≥18 years (>12 years for patients with thyroid cancer)
- Be a resident of the United States or Puerto Rico
- Have a prescription for Retevmo for an FDA-approved indication.
The application for the Retevmo MyRightDose Program is available online. The completed form should be faxed to 844-372-9043. Click here for more information on the MyRightDose Program for Retevmo, or call 833-290-2175.
Verzenio Continuous Care Program
This program provides ongoing support services for patients who have been prescribed Verzenio, including benefits investigation support, the MyRightDose Program, the Companion in Care Program, and other support services. To be eligible for the Verzenio Continuous Care Program, patients must be aged ≥18 years, have been prescribed Verzenio for an FDA-approved indication, and meet the eligibility requirements. To enroll your patient, complete the application and fax to 855-545-5957.
The Verzenio MyRightDose Program allows patients who are prescribed Verzenio to continue therapy with Verzenio at the appropriate dose, without delays or costs to the patient. Verzenio can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program. To be eligible for the program, patients must:
- Return unused pills in the preaddressed envelope, according to the instructions provided
- Be aged ≥18 years
- Be a resident of the United States or Puerto Rico
- Have a prescription for Verzenio for an FDA-approved indication.
The application for the Verzenio MyRightDose Program is available online. The completed form should be faxed to 833-665-6329. Click here for more information on the MyRightDose Program for Verzenio, or call 833-557-2417.
Once enrolled in the Verzenio Continuous Care Program, patients have access to the Companion in Care Program. This program provides patients with help from the same person every time to clarify treatment expectations, provide emotional support, answer questions about side effects, and guide patients back to your practice for medical advice.
Lilly Cares Foundation
The Lilly Cares Foundation provides the Patient Assistance Program for uninsured or underinsured patients who have been prescribed Lilly Oncology medications. Patients may be eligible for this program if they:
- Are permanent, legal residents of the United States, Puerto Rico, or the US Virgin Islands
- Have been prescribed a qualifying Lilly medication
- Have no insurance, or have Medicare Part D
- Are not enrolled in or have been denied Medicaid, full Low Income Subsidy (LIS, “Extra Help”) or Veterans (VA) Benefits (Humatrope patients with VA and Medicaid benefits may be eligible. Humatrope patients: call Lilly Cares to review eligibility requirements)
- You meet the household income guidelines for the program.
For more information, please visit LillyCares.com.
TABLE Lilly Oncology Drugs
Alimta (pemetrexed) for injection Indications
Cyramza (ramucirumab) Indications
Erbitux (cetuximab) Indications
Verzenio (abemaciclib) tablets Indications
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?
Help us fix it! Report broken links here.